Sort   by:  
 Page size 
MetabolomicsHistorical Biobanks in Breast Cancer Metabolomics - Challenges and Opportunities

BACKGROUND: Metabolomic characterization of tumours can potentially improve prediction of cancer prognosis and treatment response. Here, we describe efforts to validate previous metabolomic findings using a historical cohort of breast cancer patients and discuss challenges with u...

2022-01-24 | MTBLS1355 | MetaboLights
MetabolomicsSerum metabolomic profiles identify ER-positive early breast cancer patients at increased risk of disease recurrence in a multicentre population

PURPOSE: Detecting signals of micrometastatic disease in early breast cancer (EBC) patients could improve risk stratification and allow better tailoring of adjuvant therapies. We have previously shown that postoperative serum metabolomic profiles are predictive of relapse in a si...

2017-03-02 | MTBLS424 | MetaboLights
MetabolomicsVesicle-mediated mitochondrial clearance presents an actionable metabolic vulnerability in triple-negative breast cancer

Selective autophagy of mitochondria is known to promote survival and progression of cancer cells in various malignancies, including triple-negative breast cancer (TNBC). Here, we investigate the essential metabolic adaptations that support mitochondrial quality control in cancer cells with the ai...

2025-09-30 | MTBLS13037 | MetaboLights
MetabolomicsTargeting arginine metabolism reverses bone immunosuppressive microenvironment and metastasis in ARID1A-deficient triple negative breast cancer

Bone metastasis is a lethal consequence of breast cancer. AT-rich interaction domain 1A gene (ARID1A), a subunit of the switch/sucrose non-fermentable (SWI/SNF) complex, regulates immunosuppressive tumor microenvironment. ARID1A deficient triple negative breast cancer promotes bone metastasis.To ...

2026-03-24 | MTBLS12768 | MetaboLights
MetabolomicsTargeting PI3K inhibitor resistance in breast cancer with metabolic drugs

Activating PIK3CA mutations, present in up to 40% of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (Her2-) breast cancer (BC) patients, can be effectively targeted with the alpha isoform-specific PI3K inhibitor Alpelisib. This treatment significantly improves ...

2026-08-21 | MTBLS11671 | MetaboLights
MetabolomicsCharacterizing ex vivo models for studying lipid metabolism in triple negative breast cancer

Lipid metabolism drives cancer progression but is difficult to model using conventional methods. In vivo models provide circulating lipids, but are costly and low throughput, while in vitro models lack sufficient lipid availability in culture media. Here, we evaluate the chick chorioallantoic mem...

2026-07-16 | MTBLS13377 | MetaboLights
MetabolomicsMonounsaturated fatty acids in serum triacylglycerols are associated with response to neoadjuvant chemotherapy in breast cancer patients
Changes in cellular lipid metabolism are a common feature in most solid tumors, which occur already in early stages of the tumor progression. However, it remains unclear if the tumor-specific lipid changes can be detected at the level of systemic lipid metabolism. The objective of this study was to ...
2014-06-17 | MTBLS92 | MetaboLights
MetabolomicsCommon Metabolic Pathways Implicated in Resistance to Chemotherapy Point to a Key Mitochondrial Role in Breast Cancer
Cancer cells are known to reprogram their metabolism to adapt to adverse conditions dictated by tumor growth and microenvironment. A subtype of cancer cells with stem-like properties, known as cancer stem cells (CSC), is thought to be responsible for tumor recurrence. In this study, we demonstrated ...
2019-08-19 | MTBLS678 | MetaboLights
MetabolomicsThe Poly (ADP-Ribose) Polymerase inhibitor Veliparib and Radiation Cause Significant Cell Line Dependent Metabolic Changes in Breast Cancer Cells
Breast tumors are characterized into different subtypes based on their surface marker expression, which affects their prognosis and treatment. For example, triple negative breast cancer cells (ER-/PR-/Her2-) show reduced susceptibility towards radiotherapy and chemotherapeutic agents. Poly (ADP-ribo...
2016-11-07 | MTBLS337 | MetaboLights
MetabolomicsOxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers
Resistance to endocrine treatments and CDK4/6 inhibitors is considered a near-inevitability in most patients with estrogen receptor positive breast cancers (ER + BC). By genomic and metabolomics analyses of patients' tumours, metastasis-derived patient-derived xenografts (PDX) and isogenic cell line...
2023-06-27 | MTBLS3342 | MetaboLights
Sort   by:  
 Page size